This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) as a first-line treatment for patients with advanced unresectable hepatocellular carcinoma (HCC) that is not suitable for localized treatment. The designation of breakthrough therapy is given…
This post was originally published on this site A team of recent University of Iowa (UI) graduates who designed a bra to help breast cancer patients prevent a condition called lymphedema will use a $10,000 award to try to commercialize the undergarment. The prize from the Victoria’s Secret Pink GRL PWR Project will enable the…
This post was originally published on this site Biopharmaceutical company Longeveron will use a $3 million Alzheimer’s Association grant to advance innovative research that uses adult stem cells to target neuroinflammation in people with mild Alzheimer’s disease (AD). Funding is through the organization’s Part the Cloud global research grant program, designed to find promising targets for…
This post was originally published on this site A new report describes a woman with a very rare case of sarcoidosis involving only the spine who entered full remission after surgical removal of the lesion followed by treatment with corticosteroids. Based on this case report, researchers advised that cases of spinal sarcoidosis should be managed…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for all non-Hodgkin’s lymphoma indications of its reference product, the company announced. The therapy was also approved for people with chronic lymphocytic leukemia (CLL), as well as granulomatosis with polyangiitis (GPA)…
This post was originally published on this site Melanoma patients who become resistant to immune checkpoint inhibitors may regain susceptibility to such treatments after receiving Targovax‘s immune activator ONCOS-102, early clinical trial findings suggest. The trial is testing a combination of ONCOS-102 and the immune checkpoint inhibitor Keytruda (pembrolizumab) in advanced or surgery-ineligible melanoma patients…
This post was originally published on this site Men with prostate cancer who undergo treatment with androgen deprivation therapy (ADT) — a form of hormone therapy that aims to slow disease progression by reducing the levels of male hormones — may be more likely to develop Alzheimer’s disease and dementia, a large database study reports.…
This post was originally published on this site Women with ovarian cancer who have a family history of breast or ovarian cancer, and are younger than 45 if breast cancer in a near relative makes up that history, are more likely to have inherited BRCA mutations and could benefit from a genetic test to see if they…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone be approved to treat adults with relapsed or refractory multiple myeloma in Europe. The therapy, collectively known as the…
This post was originally published on this site Anixa Biosciences, a leading company developing anti-cancer immunotherapies, is partnering with the Cleveland Clinic to advance a vaccine against triple-negative breast cancer (TNBC) to testing in humans. “We are pleased to be able to work with Anixa to advance this technology into human trials,” Cleveland Clinic researcher…
